Nieuws en video's - UCB - Pagina 5

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) PR Newswire BRUSSELS and ATLANTA, March 28, 2022 FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, with a high likelihood of injury 3 LGS is a severe childhood-onset developmental and epileptic encephalopathy...

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting PR Newswire ATLANTA, March 26, 2022 Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis Pooled data from five Phase 3/ 3b trials showed that more than eight out of 10 patients who achieved complete skin clearance with bimekizumab at week 16, and entered open-label extension, maintained this...

UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. This consists of US$ 26.00 in cash per Zogenix share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share - Acquisition is expected to contribute to UCB's revenue growth, be dilutive to...

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show a favorable safety profile and good tolerability - UCB plans to proceed with zilucoplan regulatory submissions later this year - Results follow recent positive topline data from the Phase 3 MycarinG study investigating...

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study - The BE COMPLETE study evaluated bimekizumab in adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF treatment - BE COMPLETE is the second positive Phase 3 study for bimekizumab in active psoriatic arthritis, meeting its primary and all ranked secondary endpoints with statistically significant and clinically meaningful results - UCB plans to submit regulatory...

Shareholder Alert: Ademi LLP investigates whether Zogenix, Inc. has obtained a Fair Price in its transaction with UCB. PR Newswire MILWAUKEE, Jan. 19, 2022 MILWAUKEE , Jan. 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Zogenix (NASDAQ: ZGNX) for possible breaches of fiduciary duty and other violations of law in its transaction with UCB. Click here to learn how to join the action: https://www.ademilaw.com/case/zogenix-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or...

UCB to acquire Zogenix - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare disease therapies - Adds treatment option for specific, vulnerable patient populations with FINTEPLA® (fenfluramine) C-IV oral solution - approved for seizures associated with Dravet syndrome, with potential in other...

UCB to acquire Zogenix PR Newswire BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare disease therapies - Adds treatment option for specific, vulnerable patient populations with FINTEPLA ® (fenfluramine) C-IV oral solution - approved for seizures...

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study - The BE MOBILE 1 study met the primary and all ranked secondary endpoints, showing that bimekizumab improved outcomes in patients with active non-radiographic axial spondyloarthritis - BE MOBILE 1 is the second Phase 3 study of bimekizumab across the spectrum of axial spondyloarthritis to report positive results, and together with the first study in ankylosing spondylitis, supports the potential...

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial - BE MOBILE 2 is a Phase 3 study evaluating the efficacy and safety of bimekizumab in the treatment of patients with active ankylosing spondylitis - The trial met the primary endpoint and all ranked secondary endpoints with statistical significance PR Newswire BRUSSELS and ATLANTA, Dec. 16, 2021 BRUSSELS and ATLANTA , Dec. 16, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive...

NextSense, la fondation pour la santé cérébrale, est sortie de l’ombre avec une annonce faite lors de l’Assemblée annuelle de l’American Epilepsy Society (AES) à Chicago, où NextSense et ses partenaires ont pour la première fois présenté à leurs pairs universitaires et industriels les résultats de leurs recherches sur la détection des crises épileptiques. NextSense déverrouille la santé cérébrale avec des connaissances issues de données du monde réel, et une sagesse...

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care - 17 scientific presentations illustrate and reinforce UCB's commitment to improving the lives of people living with epilepsy - Scientific presentations provide additional insights into the efficacy and safety profile of BRIVIACT (brivaracetam) CV and VIMPAT (lacosamide) CV as well as insights into the early use of NAYZILAM (midazolam)...

UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease PR Newswire BRUSSELS, Dec. 2, 2021 -- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in Parkinson's disease -- UCB will receive upfront payment of US$150 million and is eligible to receive further milestone payments with a total potential consideration approaching US$1.5...

UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease -- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in Parkinson's disease -- UCB will receive upfront payment of US$150 million and is eligible to receive further milestone payments with a total potential consideration approaching US$1.5 billion -- Partnership an important...

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms -- The BE OPTIMAL study met the primary endpoint and all ranked secondary endpoints with statistical significance -- The study used the high treatment goal of ACR50 as the primary outcome measure -- BE OPTIMAL is the first of two Phase 3 trials evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis PR Newswire BRUSSELS...

UCB Showcases Key Rheumatology Data at ACR Convergence 2021 -- Eleven abstracts across UCB's rheumatology portfolio, including investigational bimekizumab and CIMZIA® (certolizumab pegol), underscore UCB's dedication to rheumatology -- Long-term three-year data from Phase 2b studies highlight bimekizumab's potential to improve the lives of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) -- Phase 3 C-axSpAnd open-label safety follow-up extension study shows CIMZIA...

Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit Spotlight session highlighting Sharecare's efforts to advance real-world relevance, equity, and data integrity in clinical research scheduled for Monday, Nov. 8 at 2 p.m. EST PR Newswire ATLANTA, Nov. 3, 2021 ATLANTA , Nov. 3, 2021 /PRNewswire/ -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will co-present with...

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy - New analysis led by patients from across Europe and the United States provides first-hand insight into the lived experience of myasthenia gravis - The analysis highlights five key themes that are central to the patient experience - Patient advocates behind the paper call for greater understanding of myasthenia gravis and more open dialogue between patients and...

UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab - ImageBiopsy Lab will further develop and launch an AI-based fracture identification tool based on UCB-developed BoneBot AI technology which detects the presence of "silent" or asymptomatic fractures in the spine through the use of artificial intelligence (AI). - Currently more than two-thirds of vertebral fractures are undiagnosed. Identifying them systematically has proven to be challenging for...

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab - The U.S. FDA has informed UCB via letter that the Agency was unable to complete review of the BLA for bimekizumab by the PDUFA date and is deferring action on the application - The Agency cited only the inability to conduct on-site facility inspections due to travel restrictions as the reason for deferral - UCB is committed to bringing bimekizumab to patients with moderate to severe plaque psoriasis in the U.S. as...